TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32632842

Group type: EXPERIMENTAL
Intervention: Breastfeeding initiation
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) percentile
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Birthweight
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: BMI percentile comparison based on caregiver's birthplace
Number of subjects: 370

Group type: COMPARATOR
Intervention: Breastfeeding duration
Number of subjects: 370

Group type: COMPARATOR
Intervention: Bottle feeding duration
Number of subjects: 370

Group type: COMPARATOR
Intervention: Age when solid foods were introduced
Number of subjects: 370
Study: 35538056

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Aerobic exercise + Diet
Number of subjects: 115

Group type: COMPARATOR
Intervention: No Intervention
Number of subjects: 115
Study: 35076327

Group type: EXPERIMENTAL
Intervention: Local oestrogen (oestriol) therapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 67
Study: 32975783

Group type: EXPERIMENTAL
Intervention: Ultrafiltration profiling (constantly declining UF rate)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional ultrafiltration
Number of subjects: 34
Study: 36011468

Group type: EXPERIMENTAL
Intervention: Veggie Van (VV) mobile market model intervention for one year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control sites hosting planning events
Number of subjects: 0
Study: 35549760

Group type: EXPERIMENTAL
Intervention: CBE stent (BARD®LIFESTREAM™)
Number of subjects: 106

Group type: COMPARATOR
Intervention: CSE stent (GORE® VIABAHN™)
Number of subjects: 106
Study: 33247572

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ketorolac tromethamine 20mg
Number of subjects: 40
Study: 33099947

Group type: EXPERIMENTAL
Intervention: Preoperative neo‐adjuvant chemotherapy+surgery+postoperative radiotherapy
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (surgery+postoperative radiotherapy)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: miR‐182 predictive value
Number of subjects: 143
Study: 33107363

Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery (TORS)
Number of subjects: 250
Study: 32760092

Group type: EXPERIMENTAL
Intervention: Medical honey
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 35426318

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Transdiagnostic Therapy (TD‐CBT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 128
Study: 32607811

Group type: EXPERIMENTAL
Intervention: High ADMA levels
Number of subjects: 115
Study: 32807162

Group type: EXPERIMENTAL
Intervention: Cinnamaldehyde (27 μg/mL)
Number of subjects: 33

Group type: COMPARATOR
Intervention: 0.5% sodium hypochlorite
Number of subjects: 33
Study: 36423855

Group type: EXPERIMENTAL
Intervention: Supervised home-based progressive resistance training (RT) for 22 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (CTL)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Supervised home-based progressive resistance training (RT)
Number of subjects: 31
Study: 33226605

Group type: EXPERIMENTAL
Intervention: Dual-task training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Single-task training
Number of subjects: 32
Study: 32996722

Group type: EXPERIMENTAL
Intervention: anodal tDCS (7, 13, and 20 min duration)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: hf‐tRNS (1mA for 7, 13, and 20 min duration)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: hf‐tRNS (1mA for 13 min duration)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: hf‐tRNS (1mA for 20 min duration)
Number of subjects: 15
Study: 36493503

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 211
Study: 33845098

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drink
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (no intake after midnight)
Number of subjects: 82
Study: 32957971

Group type: EXPERIMENTAL
Intervention: PACE Steps to Success intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 35429285

Group type: EXPERIMENTAL
Intervention: 101BHG‐D01 nasal spray (40 µg to 960 µg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32949027

Group type: EXPERIMENTAL
Intervention: VL20 (20% repetition velocity loss)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: VL40 (40% repetition velocity loss)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups (VL20 and VL40)
Number of subjects: 22
Study: 32779140

Group type: EXPERIMENTAL
Intervention: Opt-in choice eConsult program
Number of subjects: 305915

Group type: COMPARATOR
Intervention: Traditional referrals
Number of subjects: 305915
Study: 36055678

Group type: EXPERIMENTAL
Intervention: TOLAC (Trial of Labor After Cesarean)
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Cephalopelvic score
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Full engagement in the pelvis
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Bishop cervical maturity score
Number of subjects: 620
Study: 33141110

Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia (oxycodone)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Nurse-administered oral oxycodone
Number of subjects: 164
Study: 34848133

Group type: EXPERIMENTAL
Intervention: Riociguat 2.5 mg three times daily
Number of subjects: 396

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 396
Study: 33180322

Group type: EXPERIMENTAL
Intervention: LEAP CML-CP recommended therapy
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: LEAP CML-CP model
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: LEAP CML-CP recommendation
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Backward multivariate analysis
Number of subjects: 630
Study: 34279411

Group type: EXPERIMENTAL
Intervention: Toothpaste containing tea tree oil (TTO) and ethanolic extract of propolis (EEP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Toothpaste without tea tree oil (TTO) and ethanolic extract of propolis (EEP)
Number of subjects: 50
Study: 32172954

Group type: EXPERIMENTAL
Intervention: Intraperitoneal ropivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (Placebo)
Number of subjects: 40
Study: 35129040

Group type: EXPERIMENTAL
Intervention: 200 mg LN18178
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 400 mg LN18178
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 34332640

Group type: EXPERIMENTAL
Intervention: Training intervention for emergency medical operators
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 32
Study: 33763399

Group type: EXPERIMENTAL
Intervention: Probiotic mixture containing Saccharomyces boulardii, Lactobacillus acidophilus, Lactobacillus paracasei, Bifidobacterium lactis Bl-04, and Bifidobacterium lactis Bi-07 (Bactiol duo®)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saccharomyces boulardii
Number of subjects: 120
Study: 36060828

Group type: EXPERIMENTAL
Intervention: PRISm group
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: COPD group
Number of subjects: 343
Study: 32158015

Group type: EXPERIMENTAL
Intervention: Deep infiltrating endometriosis (group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (eutopic endometrium of adenomyosis- and endometriosis-free women)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atypical ovarian endometriosis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Deep infiltrating endometriosis and lymph node endometriosis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Endometriotic neuropathy
Number of subjects: 40
Study: 32506943

Group type: EXPERIMENTAL
Intervention: Antiphospholipid antibody IgG positivity in patients with dysglycaemia
Number of subjects: 805

Group type: COMPARATOR
Intervention: Normoglycaemic participants
Number of subjects: 805
Study: 35595254

Group type: EXPERIMENTAL
Intervention: Twice weekly factor VIII prophylaxis (10 U/kg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Thrice weekly factor VIII prophylaxis (10 U/kg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Twice weekly factor VIII prophylaxis
Number of subjects: 33

Group type: COMPARATOR
Intervention: Thrice weekly factor VIII prophylaxis
Number of subjects: 33
Study: 33079180

Group type: EXPERIMENTAL
Intervention: Leronlimab (700 mg subcutaneously, repeated after 7 days in 17 of 23 patients)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Leronlimab
Number of subjects: 23
Study: 34902549

Group type: EXPERIMENTAL
Intervention: ADAPT plus treatment as usual (TAU)
Number of subjects: 79

Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both groups (ADAPT+TAU and TAU)
Number of subjects: 79
Study: 33411586

Group type: EXPERIMENTAL
Intervention: First-line daratumumab (DRd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Second-line daratumumab (Rd)
Number of subjects: 0
Study: 35862871

Group type: EXPERIMENTAL
Intervention: Encorafenib 450 mg once daily plus binimetinib 45 mg twice daily
Number of subjects: 577

Group type: COMPARATOR
Intervention: Vemurafenib 960 mg twice daily
Number of subjects: 577

Group type: COMPARATOR
Intervention: Encorafenib 300 mg once daily
Number of subjects: 577
Study: 34605584

Group type: EXPERIMENTAL
Intervention: Extended sales hours from 3 pm to 4 pm on Saturdays starting in September 2020, December 2020, or March 2021.
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (no extended sales hours).
Number of subjects: 228
Study: 32389020

Group type: EXPERIMENTAL
Intervention: Low PNI
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Low KPS score
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Poor tumor differentiation
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Brain metastasis
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: High NLR
Number of subjects: 99
Study: 35084092

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF) using titanium miniplates and screws
Number of subjects: 20

Group type: COMPARATOR
Intervention: Closed method with inter-maxillary fixation
Number of subjects: 20
Study: 33522396

Group type: EXPERIMENTAL
Intervention: Low fat (LF) meal, 15 g of fat
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moderate fat (MF) meal, 30 g of fat
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High fat (HF) meal, 60 g of fat
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High fat (HF) meal administered twice for reproducibility
Number of subjects: 12
Study: 34811567

Group type: EXPERIMENTAL
Intervention: Multipotent adult progenitor cells (900 million cells)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 33201281

Group type: EXPERIMENTAL
Intervention: Teaching through drawing
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard teaching
Number of subjects: 80
Study: 35135619

Group type: EXPERIMENTAL
Intervention: ACTION intervention (Acceptance and Commitment Therapy) plus treatment as usual
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 80
Study: 33536677

Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM) diagnosis using WHO 2013 criteria
Number of subjects: 612

Group type: COMPARATOR
Intervention: Being overweight or obese
Number of subjects: 612

Group type: COMPARATOR
Intervention: Past history of pre‐term delivery
Number of subjects: 612

Group type: COMPARATOR
Intervention: Past history of stillbirths
Number of subjects: 612

Group type: COMPARATOR
Intervention: History of macrosmia
Number of subjects: 612

Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 612

Group type: COMPARATOR
Intervention: Having a first degree relative with diabetes mellitus
Number of subjects: 612
Study: 35140139

Group type: EXPERIMENTAL
Intervention: Gender socialisation (GS) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GS and financial literacy intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32022581

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual acupuncture (MA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Electroacupuncture (EA) vs Manual acupuncture (MA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) and Manual acupuncture (MA)
Number of subjects: 60
Study: 36376738

Group type: EXPERIMENTAL
Intervention: Spesolimab 600 mg every 4 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo every 4 weeks
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Spesolimab 600 mg every 4 weeks (sensitivity analysis)
Number of subjects: 51
Study: 33043600

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 4 weeks
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 8 weeks
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Guselkumab (both regimens)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 739
Study: 32682482

Group type: EXPERIMENTAL
Intervention: Urgent ERCP with sphincterotomy
Number of subjects: 232

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 232
Study: 34296639

Group type: EXPERIMENTAL
Intervention: Neural mobilization (straight leg raising and dorsiflexion with two‐ended slider), administered three times/week for six weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard postoperative physical therapy program only
Number of subjects: 60
Study: 32506325

Group type: EXPERIMENTAL
Intervention: Online follow-up on the first, third, and fifth days after tooth extraction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no follow-up)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Online follow-up approval by senior doctors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Online follow-up approval by young doctors
Number of subjects: 0
Study: 34174507

Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 76
Study: 34058845

Group type: EXPERIMENTAL
Intervention: Stress echocardiogram after 1 year
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Angina assessment using Seattle Angina Questionnaire
Number of subjects: 208
Study: 35477454

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 12042

Group type: COMPARATOR
Intervention: Standard glycemic control
Number of subjects: 12042
Study: 32687564

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging lesions
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: Admission systolic blood pressure
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: Baseline hematoma volume
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: Cerebral microbleeds
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: Leukoaraiosis
Number of subjects: 1752
Study: 34179697

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance for 2 years
Number of subjects: 206

Group type: COMPARATOR
Intervention: Observation after immunochemotherapy
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance
Number of subjects: 206

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 206
Study: 32056776

Group type: EXPERIMENTAL
Intervention: Super Skills for Life - adolescent version (SSL-A) over an 8-week period
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Super Skills for Life - adolescent version (SSL-A)
Number of subjects: 61

Group type: COMPARATOR
Intervention: 8-session school-work programme (placebo group)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Waitlist group (WG)
Number of subjects: 61
Study: 36190150

Group type: EXPERIMENTAL
Intervention: Osseodensification drills (OD)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Piezoelectric implant site preparation (PISP)
Number of subjects: 27
Study: 34185551

Group type: EXPERIMENTAL
Intervention: Donafenib (0.2 g orally twice daily)
Number of subjects: 668

Group type: COMPARATOR
Intervention: Sorafenib (0.4 g orally twice daily)
Number of subjects: 668
Study: 32389349

Group type: EXPERIMENTAL
Intervention: Hybrid VR during hydrotherapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: No hybrid VR during hydrotherapy
Number of subjects: 38
Study: 35083533

Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 18

Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 18
Study: 33675088

Group type: EXPERIMENTAL
Intervention: HIGH carbohydrate consumption after glycogen-lowering cycling
Number of subjects: 11

Group type: COMPARATOR
Intervention: LOW carbohydrate consumption after glycogen-lowering cycling
Number of subjects: 11

Group type: COMPARATOR
Intervention: MIX carbohydrate consumption after glycogen-lowering cycling
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: HIGH carbohydrate consumption
Number of subjects: 11

Group type: COMPARATOR
Intervention: LOW carbohydrate consumption
Number of subjects: 11
Study: 32728299

Group type: EXPERIMENTAL
Intervention: RSV F‐protein nanoparticle vaccine
Number of subjects: 4636

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4636
Study: 35449064

Group type: EXPERIMENTAL
Intervention: COVID‐19 vaccine messaging platforms (4‐min video, one‐page informational flyer, brief scripted face‐to‐face message delivered by an ED physician or nurse) during intervention weeks
Number of subjects: 1290

Group type: COMPARATOR
Intervention: N/A (control group does not receive messaging platforms)
Number of subjects: 1290
Study: 32488456

Group type: EXPERIMENTAL
Intervention: Telephone-assisted self-help (TASH) intervention for parents (12-month duration, eight booklets plus up to 14 telephone consultations)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Routine clinical care only (waitlist control group)
Number of subjects: 103
Study: 32511937

Group type: EXPERIMENTAL
Intervention: 20 sessions of computer-based working memory training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Attention training (control group)
Number of subjects: 20
Study: 35329852

Group type: EXPERIMENTAL
Intervention: Double balloon catheter plus oxytocin (12 hours with oxytocin added 6 hours after catheter insertion)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dinoprostone vaginal insert
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Double balloon catheter plus oxytocin
Number of subjects: 80
Study: 33145984

Group type: EXPERIMENTAL
Intervention: Vitamin D 3 1600 IU/day
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 33932383

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brentuximab vedotin
Number of subjects: 0
Study: 33377958

Group type: EXPERIMENTAL
Intervention: Enhanced recovery pathway (17 evidence-based pre-, intra-, and postoperative care elements)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Enhanced recovery pathway
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study: 34389605

Group type: EXPERIMENTAL
Intervention: Treat-to-target therapy
Number of subjects: 205

Group type: COMPARATOR
Intervention: Not achieving remission at 6 months
Number of subjects: 205
Study: 33559531

Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Number of subjects: 15
Study: 32531762

Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT) plus lifestyle counseling (n = 25)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Low- to moderate-intensity continuous training plus lifestyle counseling (TCT) (n = 27)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Lifestyle counseling alone (COU) (n = 23)
Number of subjects: 75
Study: 35525712

Group type: EXPERIMENTAL
Intervention: Active diagnostic strategy for pulmonary embolism (PE)
Number of subjects: 746

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 746
Study: 34590561

Group type: EXPERIMENTAL
Intervention: Self-made Qingyuan Shenghua decoction (100 mL in the morning and 100 mL in the evening for 7 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (same amount as the intervention group for 7 days)
Number of subjects: 80
Study: 35241474

Group type: EXPERIMENTAL
Intervention: Vitamin C, Vitamin D, Vitamin K2, and Zinc
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 32497602

Group type: EXPERIMENTAL
Intervention: Risperidone (RISP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Valproex sodium (DVPX)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Optimization phase
Number of subjects: 40
Study: 34982098

Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stent (DES) - NOVA intracranial sirolimus-eluting stent system
Number of subjects: 263

Group type: COMPARATOR
Intervention: Bare-Metal Stent (BMS) - Apollo intracranial stent system
Number of subjects: 263
Study: 33481914

Group type: EXPERIMENTAL
Intervention: SMS reminder for CRC screening invitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SMS reminder to complete and return FIT kit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SMS invitation for BC screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard invitation procedure
Number of subjects: 0
Study: 32131802

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring (HBPM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 35698100

Group type: EXPERIMENTAL
Intervention: Nutritional therapy group (arm A)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control group (arm B)
Number of subjects: 244